Therapy based on hypertension guidelines successfully prevented major cardiovascular events and suspended the progression of target organ damage over 20 years.
null (n=1)
Does guideline-directed therapy prevent major cardiovascular events and target organ damage progression in a patient with hypertension and high cardiovascular risk?
Long-term adherence to guideline-directed therapy successfully prevented major cardiovascular events and halted target organ damage in a high-risk hypertensive patient over 20 years.
Effect estimate: null (95% CI null)
Absolute Event Rate: 0% vs 0%
p-value: p=null
Hypertension with high cardiovascular (CV) risk is characterized by significant increase of one of the risk factors, especially cholesterol above 8 mmol/l in, for instance, familial hypercholesterolemia, or blood pressure (BP) ≥180/110 mmHg (stage III hypertension), diabetes mellitus, hypertensive left ventricular hypertrophy (LVH), moderate chronic renal failure with eGFR of 30-59 mL/min/1.73 m2 and/or calculated 10-year SCORE of 5-10%. Case report: We presented in this paper a patient with hypertension and high risk in whom diastolic hypertension, left ventricular hypertrophy, metabolic syndrome and obesity were predominant in the beginning, while diabetes mellitus prevailed in the further disease course. We presented the diagnostic protocol, as well as the risk assessment according to the European and American guidelines, and a proper selection of non-medicamentous and medicamentous therapy. The patient was treated and observed for 20 years, and the therapy based on the official hypertension guidelines was able to prevent major cardiovascular events and to suspend the progression of target organ damage in hypertension. Conclusion: Proper risk assessment in hypertensive patients, presence of risk factors and target organ damage have a decisive role in the selection of adequate therapy in hypertension. Achievement of target BP values, control of risk factors and regression of target organ damage constitute the basis of good quality of life of hypertensive patients and prevention of major cardiovascular events.
Tasić et al. (2019) conducted a null in hypertension with high cardiovascular risk (n=1). Amlodipine and Ramipril vs. none was evaluated on major cardiovascular events and progression of target organ damage (null, 95% CI null, p=null). Therapy based on hypertension guidelines successfully prevented major cardiovascular events and suspended the progression of target organ damage over 20 years.